DexCom (DXCM)
(Delayed Data from NSDQ)
$128.37 USD
+1.72 (1.36%)
Updated May 3, 2024 04:00 PM ET
After-Market: $128.34 -0.03 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
DexCom (DXCM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$149.05 | $170.00 | $120.00 | 17.69% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for DexCom comes to $149.05. The forecasts range from a low of $120.00 to a high of $170.00. The average price target represents an increase of 17.69% from the last closing price of $126.65.
Analyst Price Targets (20)
Broker Rating
DexCom currently has an average brokerage recommendation (ABR) of 1.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.24 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 4.76% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 18 | 18 | 18 |
Buy | 1 | 1 | 1 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.24 | 1.24 | 1.24 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
4/26/2024 | Raymond James | Jayson T Bedford | Strong Buy | Strong Buy |
4/25/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
3/15/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
10/27/2023 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
10/16/2023 | SVB Securities | Michael Kratky | Not Available | Strong Buy |
7/28/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.24 |
ABR (Last week) | 1.24 |
# of Recs in ABR | 21 |
Average Target Price | $149.05 |
LT Growth Rate | 33.00% |
Industry | Medical - Instruments |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | 0.39 |